相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
Alette M. Wessels et al.
JAMA NEUROLOGY (2020)
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice
Helen Crehan et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
Gerald Novak et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer's disease and related murine models
Joerg Neddens et al.
PLOS ONE (2020)
Pyroglutamation of amyloid-x-42 (Ax-42) followed by A1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
Wojciech Michno et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Investigational BACE inhibitors for the treatment of Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
Francesco Panza et al.
ANNALS OF NEUROLOGY (2019)
Secondary nucleation in amyloid formation
Mattias Tornquist et al.
CHEMICAL COMMUNICATIONS (2018)
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease
Maria Luisa Moro et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study
Maarten Timmers et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
PHARMACODYNAMICS OF THE ORAL BACE INHIBITOR JNJ-54861911 IN EARLY ALZHEIMER'S DISEASE
Johannes Streffer et al.
Alzheimers & Dementia (2016)
SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
Michael C. Irizarry et al.
Alzheimers & Dementia (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
Monitoring Blood-Brain Barrier Integrity Following Amyloid-beta Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model
Ines Blockx et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E. Kennedy et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
BACE1 Physiolocical Functions May Limit Its Use as Therapeutic Tarcet for Alzneimer's Disease
Soraia Barao et al.
TRENDS IN NEUROSCIENCES (2016)
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
Bianca Van Broeck et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD
Dietmar Rudolf Thal et al.
ACTA NEUROPATHOLOGICA (2015)
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
James P. Fuller et al.
ACTA NEUROPATHOLOGICA (2015)
Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial
Robert Lasser et al.
Alzheimers & Dementia (2015)
Building a roadmap for developing combination therapies for Alzheimer's disease
Daniel Perry et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Tiered approach into practice: scientific validation for chromatography-based assays in early development - a recommendation from the European Bioanalysis Forum
Philip Timmerman et al.
BIOANALYSIS (2015)
Building a roadmap for developing combination therapies for Alzheimer's disease
Daniel Perry et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis
Hanne Struyfs et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
Andrew D. Watt et al.
ACTA NEUROPATHOLOGICA (2014)
COMBINATION THERAPY WITH A PLAQUE-SPECIFIC ABETA ANTIBODY AND BACE INHIBITOR RESULTS IN DRAMATIC PLAQUE LOWERING IN AGED PDAPP TRANSGENIC MICE
Ronald DeMattos et al.
Alzheimers & Dementia (2014)
Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease
Ajeet Rijal Upadhaya et al.
BRAIN (2014)
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects
Robert Vassar et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice
Helmut Jacobsen et al.
JOURNAL OF NEUROSCIENCE (2014)
AZD3293 A NOVEL BACE1 INHIBITOR: SAFETY, TOLERABILITY, AND EFFECTS ON PLASMA AND CSF Aβ PEPTIDES FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION
Robert Alexander et al.
NEUROBIOLOGY OF AGING (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
Wagner Zago et al.
Alzheimers & Dementia (2013)
The global prevalence of dementia: A systematic review and metaanalysis
Martin Prince et al.
ALZHEIMERS & DEMENTIA (2013)
Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models
Jeffrey L. Frost et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Susanna Eketjall et al.
JOURNAL OF NEUROSCIENCE (2013)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Clifford R. Jack et al.
LANCET NEUROLOGY (2013)
The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration
Mark Forman et al.
Alzheimers & Dementia (2012)
BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)
Ferenc Martenyi et al.
Alzheimers & Dementia (2012)
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Reisa Sperling et al.
LANCET NEUROLOGY (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Phaedra, a Protocol-Driven System for Analysis and Validation of High-Content Imaging and Flow Cytometry
Frans Cornelissen et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Testing the Right Target and Right Drug at the Right Stage
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
β-Secretase Inhibitor Potency Is Decreased by Aberrant β-Cleavage Location of the Swedish Mutant Amyloid Precursor Protein
Hidekuni Yamakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Cerebral amyloid angiopathy and its relationship to Alzheimer's disease
Dietmar Rudolf Thal et al.
ACTA NEUROPATHOLOGICA (2008)
High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain
A. Guentert et al.
NEUROSCIENCE (2006)
Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Rebecca Radde et al.
EMBO REPORTS (2006)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases
DJ Selkoe
NATURE CELL BIOLOGY (2004)
Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology
F Bard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain
Y Harigaya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
